FDA Draft Eases Testing for Pill Strength Variations

2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY

The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.

2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI

The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.

2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS

The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.

2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA

The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.

2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO

The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.

2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER

The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.

Previous: 2025-09899 — Presidential Declaration of a Major Disaster for Public Assistance Only for the State of Mississippi

President just declared a major disaster for Mississippi because of big storms, strong winds, tornadoes, and flooding. This means local communities can get special help to fix public buildings and services. The aid starts now, so Mississippi can bounce back faster and stronger!

Next: 2025-09901 — Determination That EPINEPHRINE (Epinephrine) Solution, 1 Milligram/Milliliter, Prefilled Syringe for Intravenous Use, Was Not Withdrawn From Sale for Reasons of Safety or Effectiveness

The FDA says epinephrine prefilled syringes for IV use weren’t pulled from the market because of safety or effectiveness problems. This means drug makers can keep getting approval to sell similar versions, so patients and healthcare providers won’t face shortages. No changes in cost or timing are expected, just smooth sailing ahead for this important medicine.